Pinker v. Roche Holdings Ltd
292 F.3d 361
3rd Cir.
2002
Check Treatment
Docket

HAROLD PINKER, individuаlly and on behalf of all others similarly situtated v. ROCHE HOLDINGS LTD.

Nos. 00-4318 and 01-1562

UNITED STATES COURT OF APPEALS FOR THE THIRD CIRCUIT

May 30, 2002

2002 Decisions, Paper 313

BECKER, Chief Judge, McKEE and RENDELL, Circuit Judges.

Precedential; Argued: November 7, 2001; On Appeal From the United States District Court For the District of New Jersey (D.C. Civ. No. 99-cv-05627); District Judge: Honorable John W. Bissell, Chief Judge

2002 Decisions

Opinions of the United States Court of Appeals for the Third Circuit

5-30-2002

Pinker v. Roche Holdings Ltd

Precedential or Non-Precedential: Precedential

Docket No. 00-4318

Follow this and additional works at: http://digitalcommons.law.villanova.edu/thirdcircuit_2002

This decision is brought to you for free and open access by the Opinions of the United States Court of Appeals for the Third Circuit at Villanova University School of Law Digital Repository. It has been accepted for inclusion in 2002 Decisions by an authorized administrator of Villanova University School of Law Digital Repository. For more information, please contact Bеnjamin.Carlson@law.villanova.edu.

Recommended Citation

“Pinker v. Roche Holdings Ltd” (2002). 2002 Decisions. Paper 313. http://digitalcommons.law.villanova.edu/thirdcircuit_2002/313

PRECEDENTIAL

Filed May 30, 2002

JEFFREY H. SQUIRE, ESQUIRE

IRA M. PRESS, ESQUIRE (ARGUED)

MARK A. STRAUSS, ESQUIRE

LEWIS S. SANDLER, ESQUIRE

Kirby, McInerney & Squire LLP

830 Third Avenue

New York, NY 10022

MICHAEL M. ROSENBAUM, ESQUIRE

Budd, Larner, Gross & Rosenbaum

150 John F. Kennedy Parkway

CN 1000

Short Hills, NJ 07078

Counsel for Plaintiff-Appellant

LAWRENCE J. PORTNOY, ESQUIRE (ARGUED)

GWENN M. KALOW, ESQUIRE

MANISHA M. SHETH, ESQUIRE

Davis, Polk & Wardwell

450 Lexington Avenue

New York, NY 10017

MICHAEL R. GRIFFINGER, ESQUIRE

THOMAS VALEN, ESQUIRE

Gibbons, Del Deo, Dolan, Griffinger & Vecchione

One Riverfront Plaza

Newark, NJ 07102

Counsel for Defendant-Appellee

OPINION OF THE COURT

BECKER, Chief Judge.

American Depositary Receipts (“ADRs“) are financial instruments that allow investors in the United States to purchase and sell stock in foreign corporations in a simpler and more secure manner than trading in the underlying security in a foreign market. Harold Pinker, the plaintiff in this putative securities fraud class action, invested in ADRs of the defendant, Roche Holdings Ltd. (“Roche“), a Swiss corporation with its principal place of business in Switzerland. The gravamen of Pinker‘s action is that he purchased Roche ADRs at a price that was artificially inflated due to the company‘s misrepresentations about the competitiveness of the vitamin market when in fact its subsidiaries were engaged in a worldwide conspiracy to fix vitamin prices. As the truth about Roche‘s collusive activity began to emerge, Pinker alleges, the price of Roche ADRs dropped, and Pinker and other similarly situated investors suffered a loss. As a result, Pinker claims, Roche is liable for securities fraud in violation of Section 10(b) of the Securities Exchange Act, 15 U.S.C. S 78j(b), and Rule 10b-5, 17 C.F.R. S 240.10b-5, promulgated thereunder by the Securities and Exchange Commission (“SEC“).

The District Court dismissed Pinker‘s complaint under both Fed. R. Civ. P. 12(b)(2) (for lack of personal jurisdiction) and Fed. R. Civ. P. 12(b)(6) (for failure to adequately plead reliance). In reviewing the District Court‘s dismissal of Pinker‘s complaint under Fed. R. Civ. P. 12(b)(2), we examine the extent of Roche‘s contacts with the United States as a whole. Wе think that by sponsoring ADRs that are actively traded by American investors, Roche purposely availed itself of the American securities market and thereby evidenced the requisite minimum contacts with the United States to support the exercise of personal jurisdiction by a federal court. Moreover, in light of the fact that Roche is alleged to have made affirmative misrepresentations that misled its ADR holders, we consider the exercise of personal jurisdiction over Roche consistent with “traditional notions of fair play and substantial justice.” (quoting ). Consequently, we conclude that the District Court had in personam jurisdiction over Roche and that dismissal under Rule 12(b)(2) was inappropriate.

We also think that dismissal was improper under Rule 12(b)(6), for we are satisfied that Pinker‘s complaint adequately pled the reliance element of a securities fraud claim. Pinker‘s potential weak spot is that his complaint reflected that at the time he purchased the Roche ADRs, he was aware of a private antitrust lawsuit that had been brought against the company alleging vitamin price fixing. But the complaint also alleges that additional, more damning information about Roche‘s involvement in a price-fixing conspiracy came to light after Pinker‘s purchase of the ADRs -- specifically, the fact that Roche pled guilty to criminal antitrust charges. Although the market price of Roche ADRs may have begun to adjust for Roche‘s anti-competitive activity before Pinker‘s purchase, the complaint alleges facts from which it can be inferred that the market further adjusted for Roche‘s anti-competitive activity after Pinker‘s purchase. Pinker, therefore, has alleged sufficient facts to demonstrate that he reasonably relied on Roche‘s misrepresentations about the competitiveness of the vitamin market.

I. Facts and Procedural History

A. The Allegations of Pinker‘s Complaint

Roche is a Swiss holding company that conducts its operations through a network of subsidiary corporations. These subsidiaries manufacture and sell, among other things, pharmaceuticals, fragrances, vitamins, and chemicals throughout the world. Pinker alleges that Roche, acting in concert with its subsidiaries, entered into a worldwide conspiracy with certain competitors in the early 1990s to fix prices and allocate market share for bulk vitamins. Pinker‘s complaint alleges that at the same time it was engaging in this conspiracy, Roche made material misrepresentations and misleading statements indicating that the vitamin market was competitive. Pinker‘s complaint points to press releases and annual and semi-annual reports issued by Roche in which it described the competition in the vitamin market as, among other things, “fiercely” and “highly” competitive. In the face of this supposed competition, Pinker avers, Roche‘s statements portrayed it as a company succeeding and excelling through superior business practices when, in fact, its financial success was due to its participation in a collusive scheme.

Pinker alleges that Roche sponsored an ADR facility in the United States in 1992, and that during the class period the over-the-counter market for Roche ADRs, which had a daily trading volume of 25,000, “was an efficient market that promptly digested current information with respect to the Company from all publicly-available sources and reflected such information in Roche‘s stock price.” Consequently, Pinker contends, Roche committed a fraud on the market through its misrepresentations about the competitiveness of the vitamin market, causing him to pay an artificially inflated price for his Roche ADRs when he purchased them on April 27, 1999. Before Pinker purchased ADRs in Roche, on March 12, 1999, a Minneapolis law firm announced its filing of a class action antitrust lawsuit against Roche and eight other companies in which it alleged a conspiracy to fix prices and set volumes in the United States vitamin market. Although Pinker acknowledges that this announcement had the effect of causing Roche‘s ADR price to decline, he argues that the price declined further after the full extent of Roche‘s anti-competitive activity became known on May 20, 1999. On that date, Pinker alleges, Roche announced that it had reached a settlement with the U.S. Department of Justice undеr which it and a former company executive agreed to plead guilty to conspiracy to fix prices and allocate market share and Roche agreed to pay a record $500 million fine for its wrongdoing.

B. American Depositary Receipts (ADRs)

Because the role of ADRs is so central to our analysis of personal jurisdiction, we think it important to describe their operation in some detail. ADRs were created in 1927 to assist American investors who wanted to invest internationally, but were reluctant to do so due to regulatory and currency exchange difficulties. See Melissa Wilverding, Depository Receipts, II Global View (Brown Brothers Harriman), 2001, at 3. They also offered significant benefits to foreign companies, allоwing them to tap into the American capital market. See id. They have since become one of the preferred methods for trading foreign securities in the United States, with the value of ADRs bought and sold annually in the hundreds of billions. See Bruce L. Hertz, American Depository Receipts, 600 P.L.I./Comm. 237, 239 (1992).

An ADR is a receipt that is issued by a depositary bank that represents a specified amount of a foreign security that has been deposited with a foreign branch or agent of the depositary, known as the custodian. Id. at 240-41. The holder of an ADR is not the title owner of the underlying shares; the title owner of the underlying shares is either the depositary, the custodian, or their agent. Id. at 241. ADRs are tradeable in the same manner as any other registered American security, may be listed on any of the major exchanges in the United States or traded over the counter, and are subject to the Securities Act and the Exchange Act. Id. at 242, 246. This makes trading an ADR simpler and more secure for American investors than trading in the underlying security in the foreign market. Id. at 240.

ADRs may be either sponsored or unsponsored. An unsponsored ADR is established with little or no involvement of the issuer of the underlying security. A sponsored ADR, in contrast, is established with the active participation of the issuer of the underlying security. Id. at 242-43. An issuer who sponsors an ADR enters into an agreement with the depositary bank and the ADR owners. Id. at 243. The agreement establishes the terms of the ADRs and the rights and obligations of the pаrties, such as the ADR holders’ voting rights. Id.

SEC Form F-6 governs the registration of ADRs. Form F-6 requires that the registrant disclose important information related to the issuance of the ADR, including the terms of the depositary agreement (if any), material contracts between the depositary and the issuer, and an opinion of counsel regarding the legality of the ADRs. Id. at 288. Moreover, Form F-6 mandates that the registrant provide in its prospectus a description of the ADRs being registered, including information about fees and charges imposed on the ADR holder. Id. at 286-87. ADRs that are traded on American securities exchanges must abide by the Exchange Act‘s periodic reporting requirements. Id. at 288-89. ADRs that are not traded on exchanges, such as Roche‘s, are not subject to the Exchange Act‘s reporting requirements, but under SEC Rule 12g3-2(b) the issuer must furnish such annual reports, shareholder communications, and other materials that are required to be prepared pursuant to regulations in its home country. See id. at 289-90 (citing 17 C.F.R. S 240.12g3-2(b)).

Pursuant to these requirements, Roche filed a Form F-6 registration statement in June 1992 to register 100 million ADRs, and has since filed its annual and semi-annual reports with the SEC in compliance with Rule 12g3-2(b). It is through these annual and semi-annual reports, as well as through press releases, that Pinker alleges that Roche communicated ‍‌‌​‌​​​​​‌‌​‌​‌​​‌‌‌‌​‌​​‌‌​​‌​‌​​‌‌​‌‌‌​​​‌​‌‌‌‍to the investing public its misrepresentations about the competitiveness of the vitamin market from 1996 to 1999.

C. Procedural History

Pinker commenced this securities fraud action in the District Court for the Distriсt of New Jersey seeking to represent a class of purchasers of Roche ADRs during the period of December 3, 1996 through May 20, 1999-- the date on which Roche allegedly entered a plea agreement with the Justice Department admitting its participation in the price-fixing conspiracy. The District Court entered an order granting Pinker‘s motion to be appointed lead plaintiff. The record does not reflect any action concerning class certification. As noted above, the Court granted Roche‘s motion to dismiss Pinker‘s complaint for lack of personal jurisdiction under Fed. R. Civ. P. 12(b)(2), or, in the alternative, for failure to state a claim under Fed. R. Civ. P. 12(b)(6), and Pinker now appeals. Pinker also appeals the District Court‘s denial of his motion to amend the original complaint pursuant to Fed. R. Civ. P. 15(a), or in the alternative to amend the District Court‘s order of dismissal pursuant to Fed. R. Civ. P. 59(e) and 60(b). Because we ultimately conclude that plaintiff‘s original complaint should not have been dismissed, we need not address these issues.

II. Personal Jurisdiction

We review a district court‘s decision with respect to personal jurisdiction de novo. See . Although the plaintiff bears the burden of demonstrating the facts that establish personal jurisdiction, see , in reviewing a motion to dismiss under Rule 12(b)(2), we “must accept all of the plaintiff‘s allegations as true and construe disputed facts in favor of the plaintiff.” .

A. Background

In determining whether a court may exercise personal jurisdiction we examine the relationship among the defendant, the forum, and the litigation. See . Here, where the plaintiff‘s cause of action is related to or arises out of the defendant‘s contacts with the forum, the court is said to exercise “specific jurisdiction.” (quoting ).1 In federal court, the exercise of specific jurisdiction must satisfy the requirements of the Due Process Clause of the Fifth Amendment. See . In particular, specific jurisdiction may be exercised only when the defendant has constitutionally sufficient “minimum contacts” with the forum, (quoting ), and where subjecting the defendant to the court‘s jurisdictiоn comports with “traditional notions of fair play and substantial justice.” (quoting ).

In a case such as this, where the plaintiff‘s claim is based on a federal statute authorizing nationwide service of process, see Section 27 of the 1934 Securities Act, 15 U.S.C. S 78aa, this Court has suggested in dicta that the relevant forum for analyzing the extent of the defendant‘s contacts is the United States as a whole. For instance, in , we recognized “[t]he constitutional validity of national contacts as a jurisdictional base” where a statute “provide[s] for nationwide service of process or service wherever defendant is ‘doing business’ or ‘may be found.‘” (citations omitted). We considered the aggregation of the national contacts of an alien defendаnt “neither unfair nor unreasonable” under the Fifth Amendment in light of the fact that a federal court sits as a unit of the national government and, therefore, the territorial limitations that apply to the exercise of state court jurisdiction -- or, for that matter, federal jurisdiction in diversity cases, see -- are inapposite. .

Where Congress has spoken by authorizing nationwide service of process, therefore, as it has in the Securities Act, the jurisdiction of a federal court need not be confined by the defendant‘s ‍‌‌​‌​​​​​‌‌​‌​‌​​‌‌‌‌​‌​​‌‌​​‌​‌​​‌‌​‌‌‌​​​‌​‌‌‌‍contacts with the state in which the federal court sits. See . Following this reasoning, the district courts within this Circuit have repeatedly held that a “national contacts analysis” is apprоpriate “when appraising personal jurisdiction in a case arising under a federal statute that contains a nationwide service of process provision.” ; see also (“[A]n assessment of personal jurisdiction under [a statutory provision authorizing nationwide service of process] necessitates an inquiry into the defendant‘s contacts with the national forum.“). We too are persuaded by the reasoning of our prior decisions on the subject, and, consistent with several of our sister courts of appeals, hold that a federal court‘s personal jurisdiction may be assessed on the basis of the defendant‘s national contacts when the plaintiff‘s claim rеsts on a federal statute authorizing nationwide service of process. See ; ; ; ; , rev‘d on other grounds, ; see also (not precedential) (citing ).

We have reasoned that in assessing the sufficiency of a defendant‘s contacts with the forum, a court should look at the extent to which the defendant “availed himself of the privileges of American law and the extent to which he could reasonably anticipate being involved in litigation in the United States.” ; see also (requiring “that there be some act by which the defendant purposefully avails itself of the privilege of conducting activities within the forum State, thus invoking the benefits and protections of its laws“). In assessing whether a commercial entity has availed itself of the privileges of a forum‘s laws, jurisdiction is proper if the defendant has taken “action . . . purposefully directed toward the forum State.” (plurality opinion of O‘Connor, J.).

Once minimum contacts have been established, we assess whether the exercise of personal jurisdiction is consistent with “traditional notions of fair play and substantial justice.” (citation omitted).2 In the context of state courts, the Supreme Court has stated that this inquiry requires evaluating “the burden on the defendant, the forum State‘s interest in adjudicating the dispute, the plaintiff‘s interest in obtaining convenient and effective relief, the intеrstate judicial system‘s interest in obtaining the most effective resolution of controversies, and the shared interests of the several States in furthering fundamental substantive social policies.” (internal quotation marks omitted). In the federal court context, the inquiry will be slightly different, taking less account of federalism concerns, see , and focusing more on the national interest in furthering the policies of the law(s) under which the plaintiff is suing.

It is important to note that the application of a “fair play and substantial justice” test has generated the most controversy in cases in which a defendant has contested the jurisdiction of the particular district court in which he was being sued in addition to, or rather than, his contacts with the nation as a whole, on the basis that the forum was a particularly unfair one. See, e.g., ; . Here, by contrast, Roche does not contend that being sued in the District of New Jersey is any more unfair than being sued anywhere else in the United States. Rather, its argument focuses on its lack of sufficient contacts with the United States as a whole. Consequently, our assessment of the “fair play and substantial justice” prong need not concern itself with the propriety of litigating this action in the District Court of New Jersey vis-a-vis other district courts throughout the nation. Cf. (“[A]n alien defendant‘s preference for a particular state as a more or less convenient forum generally [should not] rise to the level of a constitutional objection.“).

B. Discussion

Pinker‘s complaint alleges that Roche sponsored an ADR facility in the United States in 1992; that these ADRs “were actively traded on the over the counter market;” and that “the average daily trading volume of Roche ADRs during the Class Period was about 25,000 ADRs.” To be precise, the complaint alleges that Roche “established” an ADR facility, not that it “sponsored” such a facility. Roche, however, conceded before the District Court that its ADR program was sponsored, a fact which is confirmed by its public filings. The complaint also alleges, as noted above, that Roche made a series of fraudulent statements in various reports and media releasеs that had the effect of artificially inflating its ADR price. Although the complaint does not specify to whom the press releases were addressed, it does allege that the releases “were carried by national newswires,” and that “Roche‘s ADRs were followed by analysts from major brokerages, including CIBC World Markets, Merrill Lynch, Salomon Smith Barney, Argus Research, Schroder & Co., Inc., and Lehmann [sic] Brothers.”

Mindful of our obligation to “accept all of the plaintiff‘s allegations as true and construe disputed facts in favor of the plaintiff,” , we view these alleged facts as sufficient to support personal jurisdiction over Roche. In our view, by sponsoring an ADR facility, Roche “purposefully avail[ed] itself ‍‌‌​‌​​​​​‌‌​‌​‌​​‌‌‌‌​‌​​‌‌​​‌​‌​​‌‌​‌‌‌​​​‌​‌‌‌‍of the privilege of сonducting activities” in the American securities market, and thereby established the requisite minimum contacts with the United States. . As discussed above, sponsored ADRs such as Roche‘s require the issuer to deposit shares with an American branch of a depositary and to enter a deposit agreement with the ADR holders defining the rights of ADR holders and the corresponding duties of the issuer. By sponsoring an ADR, therefore, Roche took affirmative steps purposefully directed at the American investing public.3 The aim of sponsoring an ADR, after all, is to allow American investors to trade equities of a foreign corporation domestically. Roche, therefore, clearly took “action” -- sponsoring an ADR in a deliberate attempt to solicit American capital -- “purposefully directed toward the [United States].” .

Roche‘s sponsorship amounted to an active marketing of its equity interests to American investors. Just as solicitation of business in the forum state is generally sufficient to establish personal jurisdiction over the defendant for claims arising out of injuries to purchasers within the forum state, see, e.g., (upholding personal jurisdiction over a defendant who solicited in the forum state a reinsurance agreement that formed the basis for plaintiff‘s breach of contract claim), so too is personal jurisdiction appropriate where a foreign corporation has directly solicited investment from the American market. A foreign corporation that purposefully avails itself of the American securities market has adequate notice that it may be haled into an American court for fraudulently manipulating that market. Although the plaintiff‘s complaint does not allege that the fraudulent media releases and annual reports were specifically directed to American investors, a foreign corporation that has created an American market for its securities can fairly expect that that market will rely on reports and media releases issued by the corporation.

Roche argues that the exercise of personal jurisdiction in this casе is inappropriate because its ADRs were not listed on any American exchanges. This factor, Roche contends, distinguishes this case from others in which federal courts have found the issuers of ADRs to be subject to personal jurisdiction. See, e.g., (foreign issuer listed ADRs on the NASDAQ). We disagree. The mere fact that its ADRs were not listed on an American stock exchange does not demonstrate that Roche did not seek to avail itself of the American securities market, for even though Roche ADRs were not traded on an exchange, the complaint alleges that Roche ADRs were actively traded on the over-the-counter market and that the average daily trading volume of Roche ADRs was about 25,000.

We also conclude that the exercise of personal jurisdiction over Roche comports with “traditional notions of fair play and substantial justice.” Roche submits that because unlisted ADRs are subject only to minimal disclosure requirements under federal securities laws, it is therefore unfair to subject Roche to the disclosure requirements of S 10(b). Roche argues that it could not have been expected to know that American investors would assume that its disclosures abided by American standards or that American investors might later claim to have been defrauded under a fraud-on-the-market theory. However, even though Roche‘s ADRs were unlisted, they were still subject to sоme reporting requirements -- namely, whatever requirements Switzerland imposes. See 17 C.F.R. S 240.12g3-2(b) (requiring foreign issuers to furnish the SEC with shareholder communications and other materials as are required to be prepared pursuant to home market regulations in order to maintain exemption from the reporting requirements applicable to American companies). Moreover, while the parties have not addressed the issue, it would appear that the alleged fraudulent misstatements of Roche, being affirmative misrepresentations and not simply material omissions, would violate the disclosure requirements of any securities regulatory regime, including Switzerland‘s.4

Additionally, we believe that the national interest in furthering the policies of the American securities regulatory system militates in favor of exercising personal jurisdiction over Roche. As explained in Section I.B, ADRs are the preferred method for trading in foreign securities in the United States in part because they are a more secure investing option for Americans than purchasing the foreign corporation‘s stock directly due to the fact that they are subject to reporting and regulatory requirements under the Securities Act and the Exchange Act. Allowing Roche to escape the personal jurisdiction of the federal courts would in essence nullify the regulatory protection that American investors seek when they purchase ADRs.5 If ADRs are subject to the United States securities regulatory regime in theory, but are exempt in practice due to the inability of American courts to exercise personal jurisdiction over the foreign corporation issuer, one would expect them to be considered a less attractive option for American investors.

In sum, we do not think it unfair or inconsistent with “traditional notions of fair play and substantial justice” to subject Roche to personal jurisdiction in a United States court when it has taken affirmative steps to market its ADRs to the American investing public, and when it is alleged to have made material misrepresentations about its business practices that have artificially inflated the market priсe of those ADRs. We therefore conclude that the District Court erred in dismissing Pinker‘s complaint pursuant to Rule 12(b)(2) for failing to adequately allege personal jurisdiction.6

III. Reliance

To state a valid claim for securities fraud under S 10(b) and Rule 10b-5, a plaintiff must allege that the defendant: (1) made a misstatement or an omission of a material fact; (2) with scienter; (3) in connection with the purchase or the sale of a security; (4) upon which the plaintiff reasonably relied; and (5) that the plaintiff‘s reliance was the proximate cause of his or her injury. See . If a plaintiff fails to allege any of these elements, the complaint must be dismissed. See .

A plaintiff may prove reasonable reliance under a fraud-on-the-market theory. See . Under this theory, a рlaintiff is entitled to a presumption of reliance if he bought securities in an efficient market; in an efficient market, the price of the security is assumed to have incorporated the alleged misrepresentations of the defendant. See id. Pinker alleges that “[a]t all relevant times, the market for Roche‘s ADRs was an efficient market that promptly digested current information with respect to the Company from all publicly-available sources and reflected such information in Roche‘s stock price.” In light of Roche‘s numerous alleged misrepresentations about the competitiveness of the vitamin market, Pinker contends that he has adequately pled reliance under a fraud-on-the-market theory because he bought Roche ADRs at a price that was artificially inflated due to the market‘s reliance on these misrepresentations.

The District Court concluded that Pinker had failed to plead reliance in light of the complaint‘s acknowledgment of both Pinker‘s and the market‘s awareness of a Minneapolis law firm‘s public announcement of its plans to sue Roche for antitrust violations on March 12, 1999. Because Pinker did not purchase his Roche ADRs until April 27, the Court concluded that the announcement of the antitrust lawsuit had been integrated into the price of Roche ADRs and that, as a result, Pinker could not show reliance under a fraud-on-the-market thеory because the market was already aware of Roche‘s anti-competitive activities at the time at which Pinker purchased his ADRs.

While we think that the complaint could have been more artfully drafted, in light of our responsibility at this stage to construe ‍‌‌​‌​​​​​‌‌​‌​‌​​‌‌‌‌​‌​​‌‌​​‌​‌​​‌‌​‌‌‌​​​‌​‌‌‌‍its allegations in the light most favorable to the plaintiff, we conclude that Pinker has adequately pled reliance.7 Although the complaint alleges that the March 12 “revelation . . . caused the share price of Roche to drop,” this allegation lies within a section of the complaint entitled “The Truth Begins to Emerge.” (Emphasis added). Later in the same section Pinker alleges that on May 20, 1999-- a point in time after he purchased his ADRs in Rоche -- Roche and a former Roche executive agreed to plead guilty to criminal antitrust charges. These allegations make clear Pinker‘s assertion that although the truth about Roche‘s anti-competitive activities might have begun to emerge to both Pinker and the market on March 12, 1999, the full extent of Roche‘s illegal activities was not disclosed until May 20, 1999.

Moreover, the disclosure of a private law firm‘s filing of an antitrust suit against Roche hardly indicated to the market with any degree of certainty that Roche had indeed engaged in anti-competitive activity. Although the market knew that Roche would have to incur legal expenses as a result of the suit, the market may well have thоught that the lawsuit was frivolous, or that at the very least Roche stood a good chance of successfully defending itself or reaching an acceptable settlement. The revelation of May 20, on the other hand, amounted to an outright admission by Roche of wrongdoing. At that point, the investing public became aware not only of Roche‘s illegal activity, but also that it had agreed to pay a record $500 million fine for its antitrust violations.8

In sum, reading the complaint in the light most favorable to the plaintiff, it is possible that the full truth about Roche‘s anti-competitive activity had not yet emerged by the time at which Pinker purchased his ADRs, and, therefore, he has adequately pled reasonable reliance under a fraud-on-the-market theory of liability.

Conclusion

Having concluded that dismissal of the plaintiff‘s complaint was inappropriate under both Rules 12(b)(2) and 12(b)(6), the order of the District Court dismissing the complaint will be reversed, and the case remanded for further proceedings.

A True Copy:

Teste:

Clerk of the United States Court of Appeals for the Third Circuit

Notes

1
1. “Specific jurisdiction” stands in contrast to “general jurisdiction,” which is established when a defendant‘s contacts with the forum are “continuous and systematic.” . If general jurisdiction exists, the contacts between the defendant and the forum need not be specifically related to the underlying cause of action in order for an exercise of personal jurisdiction over the defendant to be proper. See, e.g., . Although Pinker argues that the District Court had general jurisdiction over Roche, we consider his specific jurisdiction argument much stronger (and ultimately meritorious for the purposes of this appeal) and therefore do not address whether Roche is subject to general jurisdiction.
2
2. To be sure, there has been some debate as to whether this second prong of the International Shoe analysis ought to apply in the context of a federal statute authorizing nationwide service of process. Compare, e.g., (requiring only minimum contacts), with (requiring that the “constitutional notions of fairness and reasonableness” be met) (internal quotation marks omitted). This Court has not issued an authoritative ruling on the matter, although we have hinted that a fairness analysis consisting of more than an assessment of the defendant‘s national contacts would be appropriate. See (citing ). Because the plaintiff has not objected to the application of a “fair play and substantial justice” analysis, we will assume, without deciding, that such an analysis is appropriate in this context.
3
3. Although the plaintiff‘s complaint does not explain in detail what an ADR is and how an ADR facility is established, we believe that these facts may be judicially noticed. See Fed. R. Evid. 201(b).
4
4. Even if Roche is correct that the fraud-on-the-market theory is unique to American law and that, as a Swiss сorporation, it could not have been expected that its misrepresentations would subject it to liability under this theory, this is a problem that can be addressed by choice-of-law doctrine, for it goes to the merits of the case rather than to the question of personal jurisdiction. See (“[C]hoice of law analysis -- which focuses on all elements of a transaction, and not simply on the defendant‘s conduct -- is distinct from minimum-contacts jurisdictional analysis -- which focuses at the threshold solely on the defendant‘s purposeful connection to the forum.“).
5
5. We also note that without this regulatory protection, Roche and other foreign corporations might have a more difficult time obtaining American capital through ADR facilities.
6
6. As a holding company, Roche conducted its operations in the United States through an array of subsidiaries and sub-subsidiaries. An issue is raised in the briefs as to the extent to which the activities of these subsidiary entities are chargeable to Roche for the purposes of personal jurisdiction. We recognize that an argument can be made that the activities of Roche and these entities -- particularly, F. Hoffman-La Roche Ltd., a Swiss corporation, and the New Jersey corporations of Hoffman-La Roche, Inc., and Roche Vitamins, Inc., which, it appears, were responsible for the marketing and sale of bulk vitamins in the United States -- werе so intertwined as to justify imputing the subsidiaries’ conduct to Roche for personal jurisdiction purposes. In particular, although not alleged in Pinker‘s complaint, it could also be argued that we should judicially notice the fact that the same person, Dr. Fritz Gerber, simultaneously served as Chairman of the Board of Roche and Chairman and Chief Executive Officer of F. Hoffman-La Roche Ltd. during times relevant here. We ultimately decline to delve into these complicated legal and factual issues of corporate veil-piercing, however, because we are satisfied, for the reasons set forth above, that Roche purposefully availed itself of the American market and lеgal system through its sponsorship of an ADR facility. Although veil-piercing issues may be relevant at the merits stage of this litigation, we do not consider it necessary to address them for the purposes of Rule 12(b)(2).
7
7. We exercise de novo review over dismissal of claims under Fed. R. Civ. P. 12(b)(6). See . In evaluating the propriety of the dismissal, we accept all factual allegations as true, construe the complaint in the light most favorable to the plaintiff, and determine whether, under any reasonable reading of the complaint, the plaintiff may be entitled to relief. See .
8
8. Roche points out that although Pinker‘s complaint alleges that “Roche agreed tо plead guilty,” it was actually one of Roche‘s subsidiaries, F. Hoffman-La Roche Ltd., that entered into the plea agreement, and Roche itself was not involved. The plea agreement filed in the Northern District of Texas does indeed reflect that only the United States government and F. Hoffman-La Roche Ltd. were parties to the agreement. However, even if, despite our obligation to accept all of the complaint‘s factual allegations as true, we were to agree that Pinker‘s allegation is a factual mischaracterization, it is likely that Pinker has adequately pled reliance in light of the fact that the value of ADRs in Roche, a holding company, is necessarily tied to the actions and fluctuations in value of its subsidiary operating entities, including F. Hoffman-La Roche.